Research and Clinical Trials

Title  
ARIAD AP26113-13-301: A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer
Brief Description  
The primary objective of the study is to compare the efficacy of brigatinib to that of crizotinib in ALK-positive locally advanced or metastatic NSCLC patients naive to ALK inhibitors, as evidenced by PFS.
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Lung
Status  
OPEN
Start Date  
12/22/2016
IRB Number  
00018899
Principal Investigator  
Carrizosa, Daniel Ricardo
Contact Name  
Audrie Walls

For More Information, Contact  Audrie  , Walls
Phone:  980-442-2386 Fax:    
Email:  Audrie.Walls@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204
Close